Mylan NV (MYL)

19.14
NASDAQ : Health Technology
Prev Close 19.68
Day Low/High 19.11 / 19.78
52 Wk Low/High 16.63 / 32.23
Avg Volume 5.92M
Exchange NASDAQ
Shares Outstanding 516.13M
Market Cap 10.16B
EPS 0.70
P/E Ratio 209.00
Div & Yield N.A. (N.A)
Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid

Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid

Pharmaceutical giant Mylan (MYL) was the worst performing stock in the S&P 500 on Monday, making it TheStreet's Move of the Day.

Allergan Jumps, Mylan Slumps After Teva Deal; Stocks Slide

Allergan Jumps, Mylan Slumps After Teva Deal; Stocks Slide

Allergan (AGN) was the best performer on the S&P 500 Monday after Teva Pharmaceuticals (TEVA) agreed to buy its generic-drug business for more than $40 billion.

Chinese Stocks Post Biggest One-Day Loss in Eight Years

And four other things you need to know now.

Drugmaker Mallinckrodt Looks Very Healthy

Drugmaker Mallinckrodt Looks Very Healthy

Pharmaceutical firm's chart shows a likely move to the upside.

Chinese Stocks Go Down Again Despite Official Measures

And four other things you need to know now.

Rising Rates Won’t Slow Deal Flow Says Kellner Fund Manager

Rising Rates Won’t Slow Deal Flow Says Kellner Fund Manager

Deal flow has been massive in the first half of 2015 from healthcare to technology to insurance.

Can Biotechs' Relative Strength Be Trusted? 6 Stocks to Watch

Can Biotechs' Relative Strength Be Trusted? 6 Stocks to Watch

Sector may not be as bulletproof as we thought.

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Jim Cramer answers your Twitter questions about FireEye (FEYE) and other stocks from the floor of the New York Stock Exchange.

Health Care Mergers Are Just Getting Started

Deals coming fast and furious in the best group in town.

Deluge of Deals Isn't About to Dry Up

Acquisitions cut into overabundance of companies.

Rising Interest Rate Environment Won't Derail Merger Fund

Rising Interest Rate Environment Won't Derail Merger Fund

The Merger Fund seeks absolute returns and is not correlated to the stock market so it will fare well in a rising rate environment.

Dealmaking Frenzy Leads to Heady Days for Event-Driven Funds

Dealmaking Frenzy Leads to Heady Days for Event-Driven Funds

The surge in deal-making has created the ideal environment for merger arbitrage or event-driven funds, said K.C. Nelson, portfolio manager for the Driehaus Event Driven Fund.

Stocks Slump as Biotech Sector Drags Nasdaq From Records

Stocks Slump as Biotech Sector Drags Nasdaq From Records

Stock losses escalated in the closing minutes of Monday's session.

Amazon Leads Stock Markets; Nasdaq Extends Record Run

Amazon Leads Stock Markets; Nasdaq Extends Record Run

The Nasdaq was the clear winner on markets Friday. The tech-heavy index spiked into record territory as Amazon (AMZN), Microsoft (MSFT) and Google (GOOGL) rallied after reporting earnings.

Japanese Stocks Hit 15-Year High

And four other things you need to know now.

Market Wrap: Major Indexes End Mixed

Market Wrap: Major Indexes End Mixed

U.S. stocks were mixed on Tuesday.

Earnings and Marriage Season

Earnings and Marriage Season

Biotech companies are saying, "I do."

Deal or No Deal, Stick With Mylan

Deal or No Deal, Stick With Mylan

Teva bid highlights M&A action in health care sector.

Deal or No Deal, Stick With Mylan

Deal or No Deal, Stick With Mylan

Teva bid highlights M&A action in health care sector.

Say It With Me: Specialty Pharma

These companies are the hottest thing going.

Small-Cap M&A Flies Under the Radar

Small-Cap M&A Flies Under the Radar

Recent activity has heated up and is creating shareholder value.

Day Ahead: Good News from Overseas

Day Ahead: Good News from Overseas

But rate jitters still persist in the U.S.

Greece Said to Be Able to Pay IMF

And four other things you need to know now.

Market Wrap: Digesting the Minutes

Market Wrap: Digesting the Minutes

The Fed minutes produced little fanfare.

Mylan Deal the Rx for Drug Stocks

Mylan Deal the Rx for Drug Stocks

Even the second-tier biotechs are taking off.

Mylan Deal Is All That Shell Is Not

The ecstasy and the agony of M&A all in one day.

The 7 Pillars of Healthcare Strength

The 7 Pillars of Healthcare Strength

Here are healthcare stocks of all shares and sizes with strong charts.

Zogenix an Odd Winner at the Ballot Box

Zogenix an Odd Winner at the Ballot Box

A huge political headwind has been removed for this pharma.

How Competition Hurts a Stock

It might be good for consumers, but not for the stock.

Merger Mania Benefits Mylan

Merger Mania Benefits Mylan

Whether it's acquiring or the acquired, Mylan is building shareholder value.